$BMRN
BIOMARIN PHARMACEUTICAL INC

2020 Q2 Form 10-Q Financial Statement

#000104847720000023 Filed on August 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $429.5M $387.8M $400.7M
YoY Change 10.76% 4.0% 7.31%
Cost Of Revenue $97.97M $77.44M $89.18M
YoY Change 26.51% -2.0% 8.32%
Gross Profit $331.5M $310.3M $311.6M
YoY Change 6.83% 5.62% 7.02%
Gross Profit Margin 77.19% 80.03% 77.75%
Selling, General & Admin $175.4M $160.8M $162.2M
YoY Change 9.12% 4.88% 17.22%
% of Gross Profit 52.91% 51.8% 52.05%
Research & Development $182.1M $185.6M $183.6M
YoY Change -1.89% 5.73% -0.19%
% of Gross Profit 54.94% 59.82% 58.93%
Depreciation & Amortization $9.700M $21.53M $22.43M
YoY Change -54.94% 7.11% -5.1%
% of Gross Profit 2.93% 6.94% 7.2%
Operating Expenses $357.6M $346.4M $345.7M
YoY Change 3.22% 5.33% 7.28%
Operating Profit -$40.95M -$41.35M -$53.95M
YoY Change -0.99% 63.69% 21.59%
Interest Expense $8.048M $6.866M $6.727M
YoY Change 17.22% -43.84% -41.82%
% of Operating Profit
Other Income/Expense, Net $2.500M $500.0K $1.600M
YoY Change 400.0% -82.14% -900.0%
Pretax Income -$42.27M -$41.90M -$52.96M
YoY Change 0.9% 43.59% 4.24%
Income Tax -$13.09M -$4.460M $3.516M
% Of Pretax Income
Net Earnings -$29.18M -$37.44M -$56.47M
YoY Change -22.04% 122.93% 27.91%
Net Earnings / Revenue -6.79% -9.65% -14.09%
Basic Earnings Per Share -$0.16 -$0.21 -$0.32
Diluted Earnings Per Share -$0.16 -$0.21 -$0.32
COMMON SHARES
Basic Shares Outstanding 180.7M shares 179.0M shares 178.3M shares
Diluted Shares Outstanding 180.7M shares 179.0M shares 178.3M shares

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.380B $731.1M $894.9M
YoY Change 88.81% -46.36% -35.29%
Cash & Equivalents $818.9M $307.6M $364.4M
Short-Term Investments $561.5M $423.5M $530.5M
Other Short-Term Assets $142.1M $119.8M $93.90M
YoY Change 18.66% 49.54% 30.78%
Inventory $743.9M $578.7M $534.7M
Prepaid Expenses
Receivables $381.2M $377.2M $393.4M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.648B $1.807B $1.917B
YoY Change 46.54% -20.76% -14.47%
LONG-TERM ASSETS
Property, Plant & Equipment $1.011B $963.0M $1.005B
YoY Change 4.98% 6.94% 12.27%
Goodwill $196.2M $197.0M
YoY Change -0.43%
Intangibles $433.4M $476.6M
YoY Change -9.07%
Long-Term Investments $323.1M $375.0M $320.0M
YoY Change -13.84% 33.93% 2.04%
Other Assets $135.9M $99.46M $510.2M
YoY Change 36.6% -78.6% 16.03%
Total Long-Term Assets $2.655B $2.587B $2.519B
YoY Change 2.63% 10.32% 6.92%
TOTAL ASSETS
Total Short-Term Assets $2.648B $1.807B $1.917B
Total Long-Term Assets $2.655B $2.587B $2.519B
Total Assets $5.302B $4.393B $4.435B
YoY Change 20.68% -5.0% -3.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $205.9M $223.9M $224.4M
YoY Change -8.04% 33.27% 37.25%
Accrued Expenses $207.4M $180.6M $158.9M
YoY Change 14.84% 8.01% 20.84%
Deferred Revenue $5.350M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $373.5M $2.900M $2.900M
YoY Change 12779.31% -99.22% -99.21%
Total Short-Term Liabilities $813.3M $439.4M $501.0M
YoY Change 85.08% -45.41% -35.23%
LONG-TERM LIABILITIES
Long-Term Debt $1.078B $847.1M $843.4M
YoY Change 27.28% 3.07% 3.14%
Other Long-Term Liabilities $128.7M $103.7M $154.4M
YoY Change 24.14% -8.08% -22.26%
Total Long-Term Liabilities $128.7M $103.7M $997.8M
YoY Change 24.14% -88.91% -1.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $813.3M $439.4M $501.0M
Total Long-Term Liabilities $128.7M $103.7M $997.8M
Total Liabilities $2.065B $1.432B $1.499B
YoY Change 44.19% -17.66% -16.25%
SHAREHOLDERS EQUITY
Retained Earnings -$1.669B -$1.791B
YoY Change -6.83%
Common Stock $4.886B $4.744B
YoY Change 2.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.237B $2.961B $2.937B
YoY Change
Total Liabilities & Shareholders Equity $5.302B $4.393B $4.435B
YoY Change 20.68% -5.0% -3.51%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$29.18M -$37.44M -$56.47M
YoY Change -22.04% 122.93% 27.91%
Depreciation, Depletion And Amortization $9.700M $21.53M $22.43M
YoY Change -54.94% 7.11% -5.1%
Cash From Operating Activities $27.70M -$24.30M -$54.87M
YoY Change -213.99% -28.32% 29.07%
INVESTING ACTIVITIES
Capital Expenditures -$33.50M -$38.40M $28.76M
YoY Change -12.76% 70.67% -4.67%
Acquisitions
YoY Change
Other Investing Activities -$215.2M $58.00M $68.00K
YoY Change -471.03% 112.45% -31.31%
Cash From Investing Activities -$248.7M $19.70M -$50.48M
YoY Change -1362.44% 319.15% -29.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 563.7M -51.70M -$24.98M
YoY Change -1190.33% 204.12% 155.82%
NET CHANGE
Cash From Operating Activities 27.70M -24.30M -$54.87M
Cash From Investing Activities -248.7M 19.70M -$50.48M
Cash From Financing Activities 563.7M -51.70M -$24.98M
Net Change In Cash 342.7M -56.30M -$129.6M
YoY Change -708.7% 21.86% 4.52%
FREE CASH FLOW
Cash From Operating Activities $27.70M -$24.30M -$54.87M
Capital Expenditures -$33.50M -$38.40M $28.76M
Free Cash Flow $61.20M $14.10M -$83.62M
YoY Change 334.04% -223.68% 15.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001048477
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2019Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2020Q2 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2019Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
us-gaap:OtherAssetsNoncurrent
CY2019Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2019Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2020Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
CY2019Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2020Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
CY2020Q2 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-26727
dei Entity Registrant Name
EntityRegistrantName
BioMarin Pharmaceutical Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0397820
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
68-0397820
dei Entity Address City Or Town
EntityAddressCityOrTown
San Rafael
dei Entity Address Address Line1
EntityAddressAddressLine1
770 Lindaro Street
dei Entity Address Address Line1
EntityAddressAddressLine1
770 Lindaro Street
dei Entity Address City Or Town
EntityAddressCityOrTown
San Rafael
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94901
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94901
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
506-6700
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
BMRN
dei Trading Symbol
TradingSymbol
BMRN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
181349597 shares
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
818900000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
437446000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
561472000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
316361000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
381215000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
377404000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
743852000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
680275000 USD
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
142127000 USD
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
130657000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
2647566000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
1942143000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
323058000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
411978000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1010917000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1010868000 USD
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
433381000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
456580000 USD
CY2020Q2 us-gaap Goodwill
Goodwill
196199000 USD
CY2019Q4 us-gaap Goodwill
Goodwill
197039000 USD
CY2020Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
555137000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
549422000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
135852000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
122009000 USD
CY2020Q2 us-gaap Assets
Assets
5302110000 USD
CY2019Q4 us-gaap Assets
Assets
4690039000 USD
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
443202000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
570621000 USD
CY2020Q2 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
370100000 USD
CY2019Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
361882000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
813302000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
932503000 USD
CY2020Q2 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
1073202000 USD
CY2019Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
486238000 USD
CY2020Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
50216000 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
50793000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
128711000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
98124000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
2065431000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
1567658000 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
181148332 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
181148332 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
179383114 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
179383114 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
181000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
180000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4885637000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4832707000 USD
CY2020Q2 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
10678000 USD
CY2019Q4 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
9961000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
30050000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
20164000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1668511000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1720709000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3236679000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3122381000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5302110000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4690039000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
429485000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
387763000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
931554000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
788508000 USD
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
97967000 USD
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
77436000 USD
us-gaap Cost Of Revenue
CostOfRevenue
209341000 USD
us-gaap Cost Of Revenue
CostOfRevenue
166618000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
182139000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
185641000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
362707000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
322912000 USD
CY2020Q2 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
14912000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
324396000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
369232000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
175412000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
160754000 USD
CY2019Q2 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
20286000 USD
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
30589000 USD
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
40051000 USD
CY2020Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2019Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
15000000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
59495000 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
15000000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
470430000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
429117000 USD
us-gaap Costs And Expenses
CostsAndExpenses
867538000 USD
us-gaap Costs And Expenses
CostsAndExpenses
883813000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-40945000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-41354000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
64016000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-95305000 USD
CY2020Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-79000 USD
CY2019Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-44000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-156000 USD
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-229000 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
4291000 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
5899000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
9535000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
12197000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
8048000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
6866000 USD
us-gaap Interest Expense
InterestExpense
14963000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4460000 USD
us-gaap Interest Expense
InterestExpense
13593000 USD
CY2020Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2508000 USD
CY2019Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
470000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
647000 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
2078000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42273000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-41895000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
59079000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-94852000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-13090000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6881000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-944000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-29183000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-37435000 USD
us-gaap Net Income Loss
NetIncomeLoss
52198000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180729000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33260000 USD
us-gaap Net Income Loss
NetIncomeLoss
-93908000 USD
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179048000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180314000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
178662000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
180729000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
179048000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
184344000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178662000 shares
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39790000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
62084000 USD
us-gaap Net Income Loss
NetIncomeLoss
-93908000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51180000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81740000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
3239962000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
2936627000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3122381000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
2967940000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3236679000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
2960954000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
3236679000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
2960954000 USD
us-gaap Net Income Loss
NetIncomeLoss
52198000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48771000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
9534000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
8870000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-38000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1510000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
91956000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-799000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
4891000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-584000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
82590000 USD
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
59495000 USD
us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
15000000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-5864000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-10083000 USD
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2201000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
650000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
3603000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8028000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
31030000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
46298000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
33119000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-20441000 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
4989000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5599000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
4593000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-94425000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-37571000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
5938000 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
10279000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
12543000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79206000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66716000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
61387000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
170111000 USD
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
423477000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
321684000 USD
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
386320000 USD
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
67159000 USD
bmrn Proceeds From Sale Of Nonfinancial Assets
ProceedsFromSaleOfNonfinancialAssets
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
10786000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
5770000 USD
bmrn Payments To Acquire Debt Securities Available For Sale Non Marketable
PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable
8709000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
50000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
bmrn Payments To Acquire Debt Securities Available For Sale Non Marketable
PaymentsToAcquireDebtSecuritiesAvailableForSaleNonMarketable
0 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
722000 USD
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
808000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-171347000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30808000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
46927000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
19013000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
36645000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
36900000 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 USD
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
57507000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
585782000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-2047000 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1347000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
544017000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-76741000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-3759000 USD
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
350000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
381454000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-186405000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
437446000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
493982000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
818900000 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
307577000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
2960000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
3933000 USD
us-gaap Interest Paid Net
InterestPaidNet
4154000 USD
us-gaap Interest Paid Net
InterestPaidNet
4295000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
-23259000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets
-3467000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
-2523000 USD
bmrn Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets
SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets
1691000 USD
us-gaap Nature Of Operations
NatureOfOperations
NATURE OF OPERATIONS<div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">BioMarin Pharmaceutical Inc. (the Company) is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents and investments and through proceeds from debt or equity offerings, commercial borrowing, or through collaborative agreements with corporate partners. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital.</span></div>
us-gaap Basis Of Accounting
BasisOfAccounting
BASIS OF PRESENTATION<div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to United States (U.S.) generally accepted accounting principles (U.S. GAAP) and the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. GAAP for complete financial statements, although the Company believes that the disclosures herein are adequate to ensure that the information presented is not misleading. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K. The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020 or any other period.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">On January 1, 2020, the Company adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> (ASU 2016-13), as amended, using a modified retrospective approach. The standard has amended the guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than by reducing the carrying amount under the current, other-than-temporary impairment model. Results for reporting periods beginning January 1, 2020 are presented under ASU 2016-13 and the adoption of this standard had no impact on the Company’s Financial Statements.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the novel coronavirus disease (referred to as COVID-19) pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including revenues, expenses, reserves and allowances, manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods.</span></div><div style="text-indent:36pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q, and has concluded that there were no subsequent events or transactions that occurred subsequent to the balance sheet date prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements.</span></div>
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
818900000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
561472000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4713000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
323058000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1161152000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1694215000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
9274000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
59000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1703430000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
80000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1165785000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
437446000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
316361000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
411978000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
629156000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
652734000 USD
CY2020Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
195775000 USD
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
196154000 USD
CY2020Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
433381000 USD
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
456580000 USD
CY2019Q2 us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
15000000.0 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1602750000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1559968000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
591833000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
549100000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1010917000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1010868000 USD
CY2020Q2 us-gaap Depreciation
Depreciation
22042000 USD
CY2019Q2 us-gaap Depreciation
Depreciation
21529000 USD
us-gaap Depreciation
Depreciation
43562000 USD
us-gaap Depreciation
Depreciation
42968000 USD
CY2020Q2 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
11934000 USD
CY2019Q2 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
8570000 USD
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
23170000 USD
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
15087000 USD
CY2020Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
81132000 USD
CY2019Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
74442000 USD
CY2020Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
370148000 USD
CY2019Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
349978000 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
292572000 USD
CY2020Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
7594000 USD
CY2019Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
8395000 USD
CY2020Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7435000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
255855000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
743852000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
680275000 USD
CY2020Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
205870000 USD
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
240981000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
115120000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
192467000 USD
CY2020Q2 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
63542000 USD
CY2019Q4 bmrn Accrued Government And Other Rebates
AccruedGovernmentAndOtherRebates
57163000 USD
CY2020Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
20687000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
30797000 USD
CY2020Q2 bmrn Accrued Lease Liabilities Current
AccruedLeaseLiabilitiesCurrent
11387000 USD
CY2019Q4 bmrn Accrued Lease Liabilities Current
AccruedLeaseLiabilitiesCurrent
10700000 USD
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
10448000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
5350000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13037000 USD
CY2020Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6217000 USD
CY2019Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
6633000 USD
CY2020Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
443202000 USD
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
570621000 USD
CY2020Q2 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
36368000 USD
CY2019Q4 us-gaap Derivative Fair Value Of Derivative Asset
DerivativeFairValueOfDerivativeAsset
33592000 USD
CY2020Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
11854000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7451000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
47246000 USD
CY2019Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
15941000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
470430000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
429117000 USD
us-gaap Costs And Expenses
CostsAndExpenses
867538000 USD
us-gaap Costs And Expenses
CostsAndExpenses
883813000 USD
us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
15000000.0 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
49045000 USD
CY2020Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
9377000 USD
CY2019Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
10389000 USD
CY2020Q2 bmrn Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
56623000 USD
CY2019Q4 bmrn Operating And Finance Lease Right Of Use Asset
OperatingAndFinanceLeaseRightOfUseAsset
59434000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
8028000 USD
CY2020Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3359000 USD
CY2020Q2 bmrn Operating And Finance Lease Liability Payments Due
OperatingAndFinanceLeaseLiabilityPaymentsDue
69262000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10374000 USD
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
3249000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41869000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
44092000 USD
CY2020Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4959000 USD
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
6708000 USD
CY2020Q2 bmrn Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
58215000 USD
CY2019Q4 bmrn Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
61500000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6154000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1849000 USD
CY2020Q2 bmrn Operating And Finance Lease Liability Payments Remainder Of Fiscal Year
OperatingAndFinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
8003000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9514000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3057000 USD
CY2020Q2 bmrn Operating And Finance Lease Liability Payments Due Year One
OperatingAndFinanceLeaseLiabilityPaymentsDueYearOne
12571000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8844000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
2335000 USD
CY2020Q2 bmrn Operating And Finance Lease Liability Payments Due Year Two
OperatingAndFinanceLeaseLiabilityPaymentsDueYearTwo
11179000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
7913000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
1750000 USD
CY2020Q2 bmrn Operating And Finance Lease Liability Payments Due Year Three
OperatingAndFinanceLeaseLiabilityPaymentsDueYearThree
9663000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6104000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0 USD
CY2020Q2 bmrn Operating And Finance Lease Liability Payments Due Year Four
OperatingAndFinanceLeaseLiabilityPaymentsDueYearFour
6104000 USD
CY2020Q2 bmrn Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
21742000 USD
CY2020Q2 bmrn Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
0 USD
CY2020Q2 bmrn Operating And Finance Lease Liability Payments Due After Year Four
OperatingAndFinanceLeaseLiabilityPaymentsDueAfterYearFour
21742000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
60271000 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
8991000 USD
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.052
CY2020Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.053
CY2019Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.054
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.051
CY2020Q2 bmrn Operating Leases Not Yet Commenced Expected To Commence By End Of Fiscal Year
OperatingLeasesNotYetCommencedExpectedToCommenceByEndOfFiscalYear
1 lease
us-gaap Operating Lease Payments
OperatingLeasePayments
3712000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
3712000 USD
CY2020Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
673000 USD
CY2020Q2 bmrn Operating And Finance Lease Liability Undiscounted Excess Amount
OperatingAndFinanceLeaseLiabilityUndiscountedExcessAmount
11047000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
49897000 USD
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
8318000 USD
CY2020Q2 bmrn Operating And Finance Lease Liability
OperatingAndFinanceLeaseLiability
58215000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
3853000 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
3990000 USD
us-gaap Lease Cost
LeaseCost
7433000 USD
us-gaap Lease Cost
LeaseCost
7942000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M18D
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M12D
CY2020Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2019Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M18D
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
244000 USD
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
312000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2056000 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1346000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2881000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8909000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
472000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
72000 USD
CY2020Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
1500000000 USD
CY2020Q2 us-gaap Convertible Debt
ConvertibleDebt
1443302000 USD
CY2019Q4 us-gaap Convertible Debt
ConvertibleDebt
848120000 USD
CY2020Q2 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
1805649000 USD
CY2019Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
933309000 USD
CY2020Q2 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
3782000 USD
CY2020Q2 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
6493000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
1366000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4077000 USD
CY2019Q2 us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
1913000 USD
CY2019Q2 us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
3512000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
756000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-2355000 USD
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
22093000 USD
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
11149000 USD
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
1058000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
9886000 USD
us-gaap Oci Before Reclassifications Before Tax Attributable To Parent
OciBeforeReclassificationsBeforeTaxAttributableToParent
18192000 USD
us-gaap Reclassification From Aoci Current Period Before Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent
4478000 USD
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
1546000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
12168000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
429485000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
387763000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
931554000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
788508000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
44962000 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
39829000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91956000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
82590000 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
5500000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
10000000.0 USD
CY2019Q2 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
4300000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
8100000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-29183000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-37435000 USD
us-gaap Net Income Loss
NetIncomeLoss
52198000 USD
us-gaap Net Income Loss
NetIncomeLoss
-93908000 USD
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180729000 shares
CY2019Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
179048000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
180314000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
178662000 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
180729000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
184344000 shares
CY2019Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
179048000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
178662000 shares
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2019Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2019Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25091000 shares
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20248000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21060000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20248000 shares
bmrn Contingent Payments Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones
616600000 USD
CY2020Q2 bmrn Contingent Liability Accrual Sales And Licensing Milestones
ContingentLiabilityAccrualSalesAndLicensingMilestones
50200000 USD

Files In Submission

Name View Source Status
0001048477-20-000023-index-headers.html Edgar Link pending
0001048477-20-000023-index.html Edgar Link pending
0001048477-20-000023.txt Edgar Link pending
0001048477-20-000023-xbrl.zip Edgar Link pending
bmrn-20200630.htm Edgar Link pending
bmrn-20200630.xsd Edgar Link pending
bmrn-20200630_cal.xml Edgar Link unprocessable
bmrn-20200630_def.xml Edgar Link unprocessable
bmrn-20200630_htm.xml Edgar Link completed
bmrn-20200630_lab.xml Edgar Link unprocessable
bmrn-20200630_pre.xml Edgar Link unprocessable
exhibit311-30jun20x10q.htm Edgar Link pending
exhibit312-30jun20x10q.htm Edgar Link pending
exhibit321-30jun20x10q.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending